Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

Folschweiller, Nicolas; Behre, Ulrich; Dionne, Marc; Durando, Paolo; Esposito, Susanna; Ferguson, Linda; Ferguson, Murdo; Hillemanns, Peter; McNeil, Shelly; Peters, Klaus; Ramjattan, Brian; Schwarz, Tino F.; Supparatpinyo, Khuanchai; Suryakirian, Pemmaraju V; Janssens, Michel; Moris, Philippe; Decreux, Annabelle; Poncelet, Sylviane; Struyf, Frank

doi:10.1093/infdis/jiy743

Cited by 12 publications

(8 citation statements)

References 12 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the concept of established infection could potentially be applied to each HPV genotype. Furthermore, available HPV vaccines are safe and tolerable [18–20] and a persistent cross-reactive immune response against HR-HPV not covered by the vaccine was shown in vaccinated women [21]. However, vaccination has a clinically relevant role also in subjects with established HPV infection [13, 22].…”

Section: Discussionmentioning

confidence: 99%

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications

et al. 2019

View full text Add to dashboard Cite

Background Few studies focused on longitudinal modifications over time of high-risk HPV (HR-HPV) at anal and oral sites in HIV+ men who have sex with men (MSM). Methods We described patterns and longitudinal changes of HR-HPV detection and the prevalence of HR-HPV covered by the nonavalent HPV vaccine (vax-HPV) at oral and anal sites in 165 HIV+ MSM followed in an Italian hospital. The samples were collected at baseline and after 24 months (follow-up). The presence of HPV was investigated with Inno-LiPA HPV Genotyping Extra II. Results Median age was 44 years (IQR 36–53), median CD4+ cell count at nadir was 312 cells/mm 3 (IQR 187–450). A total of 120 subjects (72.7%) were receiving successful antiretroviral therapy (ART). At baseline and follow-up, the frequency of HR-HPV was significantly higher in the anal site (65.4% vs 9.4 and 62.4% vs 6.8%, respectively). Only 2.9% of subjects were persistently HR-HPV negative at both sites. All oral HR-HPV were single at baseline vs 54.6% at baseline at the anal site ( p = 0.005), and all oral HR-HPV were single at follow-up vs 54.4% at anal site at follow-up ( p = 0.002). The lowest rate of concordance between the oral and anal results was found for HR-HPV detection; almost all HR-HPV positive results at both anal and oral sites had different HR-HPV.The most frequent HR-HPV in anal swabs at baseline and follow-up were HPV-16 and HPV-52.At follow-up at anal site, 37.5% of patients had different HR-HPV genotypes respect to baseline, 28.8% of subjects with 1 HR-HPV at baseline had an increased number of HR-HPV, and patients on ART showed a lower frequency of confirmed anal HR-HPV detection than untreated patients ( p = 0.03) over time. Additionally,54.6 and 50.5% of patients had only HR-vax-HPV at anal site at baseline and follow-up, respectively; 15.2% had only HR-vax-HPV at baseline and follow-up. Conclusions We believe that it is important testing multiple sites over time in HIV-positive MSM. ART seems to protect men from anal HR-HPV confirmed detection. Vaccination programmes could reduce the number of HR-HPV genotypes at anal site and the risk of the first HR-HPV acquisition at the oral site. Electronic supplementary material The online version of this article (10.1186/s12889-019-7004-x) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported cross-NAbs to HPV31 and 45, one month following two or three doses of 2vHPV or 4vHPV immunisation, at approximately 100-fold lower levels than vaccine-type NAb [16][17][18][19]. These cross-NAbs were found to persist for at least 5 and 2 years for 2vHPV and 4vHPV, respectively [16,17,25,26]. Our data extends these observations for HPV31 to six years (approximately 100-fold lower levels than vaccine-type NAb observed previously [22]), as well as to girls who received two doses of 4vHPV, suggesting that two doses given to girls under 15 years old may be sufficient to induce cross-protection to HPV31 in the long-term.…”

Section: Discussionmentioning

confidence: 92%

Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules

et al. 2019

View full text Add to dashboard Cite

The duration of cross-neutralising antibody responses (cross-NAb) following HPV immunisation is unknown. We compared cross-NAb responses in cohort of girls who were either unimmunised or had received immunisation with one, two or three doses of 4vHPV (Gardasil®, Merck Inc., Kenilworth, NJ, USA) six years earlier, before and one month after a booster dose of 2vHPV (Cervarix®, GSK, Brentford, UK). NAb to potentially cross-reactive HPV genotypes 31, 33, 45, 52 and 58 were measured using a HPV pseudovirion-based neutralisation assay. Girls who had previously received at least one dose of 4vHPV had significantly higher NAb titres for HPV31 when compared with unimmunised girls, whereas no difference in NAb titre was observed for four other genotypes (33, 45, 52 and 58). Following a single further immunisation with 2vHPV, NAb titres to each of the five tested HPV genotypes were comparable for girls who previously received one, two or three doses of 4vHPV, and were significantly higher than for previously unimmunised girls. Immunisation with one, two or three doses of 4vHPV induced NAb to HPV31 that persisted for six years, but there was no persistence of NAb to HPV33, 45, 52 or 58. Our results suggest that one or two doses of 4vHPV may provide long-term protection against HPV31.

show abstract

“…For the 2vHPV vaccine, similar antibody concentrations against HPV31 and HPV45 were measured up to 5 y after both two and three doses of vaccination. 72 For the 4vHPV vaccine, higher antibody concentrations against HPV31 were observed up to 6 y after one-, two-, or three-dose-vaccination as compared to no vaccination, but this was not observed for other cross-protective serotypes. 82 This difference in antibody response against cross-protective types between vaccines might be due to the AS04 adjuvant system used in the 2vHPV vaccine, which is claimed to induce a broader immune response and may hence lead to higher antibody levels.…”

Section: Immune Responses Following Fewer Than Three Doses Of Hpv Vac...mentioning

confidence: 85%

“…Again, this level of cross-protection was higher for the 2vHPV compared to the 4vHPV vaccine. 72 Generally speaking, although cell-mediated immune effectors provide information on the responsiveness to the vaccine, they do not directly indicate how well the vaccine protects or how long antibodies are maintained (which is due to the production by LLPCs). 22 Nevertheless, further research on the long-term persistence of memory B- and T-cells could provide an indication for the sustainability of protection from disease, as is the case in hepatitis B studies.…”

Section: Long-term Immune Responses Following Three Doses Of Hpv Vacc...mentioning

confidence: 99%

Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge

Hoes

Pasmans

Klooster

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The licensed HPV vaccines are highly efficacious and induce high levels of neutralizing antibody levels, the assumed mediators of protection. However, a correlate of protection against HPV is lacking, and the evidence is still limited as to long-term persistence of antibodies, especially following reduced dosing schedules. The World Health Organization (WHO) urges immunization of young girls as part of the strategy to eliminate cervical cancer, thus long-lasting protection is required. The current review describes longterm follow-up regarding vaccine-induced seropositivity and antibody level development following the different vaccines and dosing schedules. Implications and opportunities of long-term vaccine-induced immune responses are discussed, such as the gaps in monitoring of long-term immunogenicity, the possibilities of reduced dosing schedules, and the importance of evidence for durable immunity.

show abstract

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine

Cited by 12 publications

References 12 publications

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications

Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules

Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge

Contact Info

Product

Resources

About